tradingkey.logo

Guardant Health Inc

GH
查看详细走势图
101.850USD
+3.490+3.55%
收盘 02/06, 16:00美东报价延迟15分钟
12.73B总市值
亏损市盈率 TTM

Guardant Health Inc

101.850
+3.490+3.55%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+3.55%

5天

-10.69%

1月

-7.35%

6月

+102.12%

今年开始到现在

-0.28%

1年

+129.03%

查看详细走势图

TradingKey Guardant Health Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Guardant Health Inc当前公司基本面数据相对健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在医疗设备与耗材行业排名47/205位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价121.52。中期看,股价处于平稳状态。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Guardant Health Inc评分

相关信息

行业排名
47 / 205
全市场排名
137 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Guardant Health Inc亮点

亮点风险
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
业绩高增长
公司营业收入稳步增长,连续3年增长64.39%
估值低估
公司最新PE估值-31.70,处于3年历史低位
机构减仓
最新机构持股125.58M股,环比减少11.91%
雷·达里奥持仓
明星投资者雷·达里奥持仓,最新持仓市值4.01K

分析师目标

根据 24 位分析师
买入
评级
121.520
目标均价
+14.48%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Guardant Health Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Guardant Health Inc简介

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
公司代码GH
公司Guardant Health Inc
CEOTalasaz (Amirali)
网址https://guardanthealth.com/
KeyAI